Hythiam, Inc. (NASDAQ: HYTM) announced today that the results of a double-blind, placebo-controlled study on the impact of the medical ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE